BioROSA Technologies Inc.
BioROSA Technologies is developing blood-based biomarkers for early detection and screening for Autism Spectrum Disorder using machine learning and metabolomics
- Stage Product In Development
- Industry Biotechnology
- Location Boston, MA, USA
- Currency USD
- Founded May 2018
- Employees 3
- Incorporation Type C-corp
- Website biorosa.com
Company Summary
Today Autism is diagnosed based on the presence of behavioral symptoms in early life. There is no blood test that can predict autism or diagnose the challenging condition. Additionally, there are no medical treatments that have been created for autism. BioROSA technologies has the first broad-spectrum blood test performing at 95.2% sensitivity, 91.5% specificity for early detection of autism in infancy and a platform to develop novel treatments.
Team
Previous Investors
-
IndieBio/SOSVUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.